Update: 21.03.2021
Last week: 10 week 2022 (7.02.2022 - 13.03.2022)
Last full month: Feb 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 2 881 | -8.5% | 58.6% | 1.1 | 1 291 824 | -9.5% | 84.3% | 0.5 | -10.3% |
| MoM | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| YTD | 20 674 | 2.4% | 53.8% | -5.1 | 9 181 650 | 29.7% | 81.5% | 0.1 | 12.1% |
| MAT | 118 097 | -22.4% | 54.8% | -6.8 | 47 714 967 | 2.7% | 80.3% | -0.8 | -12.8% |
| CAPSICAM | |||||||||
| WoW | 21 983 | -5.0% | 3.7% | -0.1 | 9 051 541 | -4.3% | 3.8% | -0.1 | -2.4% |
| MoM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| YTD | 180 995 | -11.9% | 3.8% | -0.2 | 74 129 670 | -14.4% | 4.0% | -0.7 | -7.2% |
| MAT | 1 040 681 | -20.9% | 3.4% | -0.3 | 426 460 231 | -12.8% | 3.6% | -0.4 | -13.9% |
| MILDRONATE | |||||||||
| WoW | 126 882 | -0.8% | 22.6% | 0.5 | 62 931 815 | 2.8% | 21.8% | 0.9 | -3.0% |
| MoM | 507 422 | 17.9% | 21.8% | 1 | 242 156 427 | 38.3% | 20.6% | 2.7 | 12.5% |
| YTD | 890 557 | 17.1% | 16.4% | 1.4 | 393 249 783 | 20.8% | 15.5% | 1.2 | 7.1% |
| MAT | 4 925 669 | 10.0% | 16.7% | 2.6 | 2 001 126 601 | 13.2% | 14.8% | 2 | -7.1% |
| SULFARGIN | |||||||||
| WoW | 3 356 | -13.1% | 1.0% | -0.1 | 1 627 973 | -11.1% | 1.3% | -0.1 | -4.0% |
| MoM | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| YTD | 26 321 | 3.0% | 1.0% | 0.1 | 12 756 179 | 7.3% | 1.3% | 0.3 | -7.8% |
| MAT | 164 922 | -20.8% | 0.8% | -0.1 | 80 623 217 | -9.2% | 1.2% | 0 | -11.5% |
| VIPROSAL | |||||||||
| WoW | 28 108 | -3.7% | 4.3% | 0 | 11 166 351 | -3.1% | 4.3% | 0 | -3.7% |
| MoM | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| YTD | 230 845 | 30.0% | 4.4% | 1.2 | 90 969 323 | 32.2% | 4.5% | 1 | -5.2% |
| MAT | 1 296 774 | -6.5% | 3.9% | 0.3 | 493 454 614 | 0.7% | 3.9% | 0.1 | -13.8% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 2 881 | -8.5% | 58.6% | 1.1 | 1 291 824 | -9.5% | 84.3% | 0.5 | -10.3% |
| KAPSIKAM | 21 983 | -5.0% | 3.7% | -0.1 | 9 051 541 | -4.3% | 3.8% | -0.1 | -2.4% |
| MILDRONATE | 126 882 | -0.8% | 22.6% | 0.5 | 62 931 815 | 2.8% | 21.8% | 0.9 | -3.0% |
| SULFARGIN | 3 356 | -13.1% | 1.0% | -0.1 | 1 627 973 | -11.1% | 1.3% | -0.1 | -4.0% |
| VIPROSAL | 28 108 | -3.7% | 4.3% | 0 | 11 166 351 | -3.1% | 4.3% | 0 | -3.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| KAPSIKAM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| MILDRONATE | 507 422 | 17.9% | 21.8% | 1 | 242 156 427 | 38.3% | 20.6% | 2.7 | 12.5% |
| SULFARGIN | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| VIPROSAL | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 20 674 | 2.4% | 53.8% | -5.1 | 9 181 650 | 29.7% | 81.5% | 0.1 | 12.1% |
| KAPSIKAM | 180 995 | -11.9% | 3.8% | -0.2 | 74 129 670 | -14.4% | 4.0% | -0.7 | -7.2% |
| MILDRONATE | 890 557 | 17.1% | 16.4% | 1.4 | 393 249 783 | 20.8% | 15.5% | 1.2 | 7.1% |
| SULFARGIN | 26 321 | 3.0% | 1.0% | 0.1 | 12 756 179 | 7.3% | 1.3% | 0.3 | -7.8% |
| VIPROSAL | 230 845 | 30.0% | 4.4% | 1.2 | 90 969 323 | 32.2% | 4.5% | 1 | -5.2% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 118 097 | -22.4% | 54.8% | -6.8 | 47 714 967 | 2.7% | 80.3% | -0.8 | -12.8% |
| KAPSIKAM | 1 040 681 | -20.9% | 3.4% | -0.3 | 426 460 231 | -12.8% | 3.6% | -0.4 | -13.9% |
| MILDRONATE | 4 925 669 | 10.0% | 16.7% | 2.6 | 2 001 126 601 | 13.2% | 14.8% | 2 | -7.1% |
| SULFARGIN | 164 922 | -20.8% | 0.8% | -0.1 | 80 623 217 | -9.2% | 1.2% | 0 | -11.5% |
| VIPROSAL | 1 296 774 | -6.5% | 3.9% | 0.3 | 493 454 614 | 0.7% | 3.9% | 0.1 | -13.8% |
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "KAPSIKAM"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"
## [1] "KAPSIKAM"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 250 MG #20"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 250 MG #20"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs